



(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
02.05.2003 Bulletin 2003/18

(21) Application number: **99948994.1**

(22) Date of filing: **11.10.1999**

(51) Int Cl.7: **C07J 1/00, A61K 31/565**

(86) International application number:
PCT/EP99/07768

(87) International publication number:
WO 00/023460 (27.04.2000 Gazette 2000/17)

(54) **HIGH PURITY COMPOUND**
(7ALPHA,17ALPHA)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE
(7ALPHA,17ALPHA)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5-(10)-EN-20-YN-3-ON ALS
REINE VERBINDUNG

COMPOSE A DEGRE ELEVE DE PURETE RENFERMANT
(7ALPHA,17ALPHA)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: **16.10.1998 EP 98203460**

(43) Date of publication of application:
08.08.2001 Bulletin 2001/32

(60) Divisional application:
02022689.0 / 1 275 379

(73) Proprietor: **Akzo Nobel N.V.**
6824 BM Arnhem (NL)

(72) Inventors:
• **KIRCHHOLTES, Peter, Huub, Gerard, Maria**
NL-5345 HN Oss (NL)
• **SAS, Gerard, Arnoud, Jozef, Maria, Theresia**
NL-5461 KL Veghel (NL)

(74) Representative: **Hogenbirk, Marijke**
P.O. Box 20
5340 BH Oss (NL)

(56) References cited:
EP-A- 0 159 739 EP-A- 0 389 035
EP-A- 0 613 687 EP-A- 0 707 848
WO-A-89/09058 WO-A-98/39012
WO-A-98/47517 FR-A- 1 583 441
US-A- 3 340 279 US-A- 3 432 528
US-A- 3 475 465 US-A- 3 576 828


- **VAN VLIET N P ET AL: "An alternative synthesis of 17.beta.-hydroxy-7.alpha.-methyl-19-nor-17.alpha.-pregn-5(10)-en-20-yn-3-one (Org OD 14)" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS., vol. 105, no. 4, April 1986 (1986-04), pages 111-115, XP002099865 AMSTERDAM NL**
- **DECLERCQ J P ET AL: "Conformational analysis of 3-oxo 5(10)-unsaturated steroids. Single-crystal x-ray structure analysis of 17-hydroxy-7.alpha.-methyl-19-nor-17.alpha.-pregn-5(10)-en-20-yn-3-one (Org OD 14)" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS., vol. 103, no. 5, May 1984 (1984-05), pages 145-147, XP002099866 AMSTERDAM NL**
- **WIELAND P ET AL: "Steroids. CCXI. Synthesis of 7.alpha.-methyl-3-oxo-19-norandrosta-4,9,11-trienes" HELVETICA CHIMICA ACTA, vol. 50, no. 6, 21 September 1967 (1967-09-21), pages 1453-1461, XP002099867 BASEL CH**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] The invention relates to a high purity (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, a method for the preparation of this compound for use in the pharmaceutical composition as well as a pharmaceutical composition prepared by admixing a pharmaceutically suitable carrier and the high purity composition.

[0002] The compound (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (Tibolone) having the structural formula 1:



Formula 1

is known, for example from US 3,340,279 and US Patent 4,701,450. The method described in these patents leads to a compound having combined oestrogenic, progestagenic and androgenic characteristics. This compound is used in medicaments having gonadomimetic, ovulation-inhibiting or immuno-modulating action.

[0003] Compositions comprising Tibolone and a pharmaceutically acceptable solid carrier have been described in EP 389 035. Tablets are available on the market under the name of Livial®.

[0004] The known tablets can be stable stored very well for, typically, 2 years at ambient temperature. A sufficiently humid atmosphere (e.g. 50 - 70 % relative humidity) makes for a better storage stability than a relatively dry atmosphere (e.g. 45% relative humidity or below that).

[0005] A problem in the preparation of pharmaceutical dosage units is that during the preparation the relative amount of impurities may increase. In particular, the amount of one of the impurities which is already present in the bulk preparation i.e. (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one (Org OM38) tends to increase during the process of making pharmaceutical dosage units. It is furthermore known that the amounts of Org OM38 in compositions comprising Tibolone increase upon storage.

[0006] The end of shelf life specification with respect to the amount of Org OM38 formed during storage is 5%. A minimum acceptable shelf life period for these dosage units is 1 year. It is an object of the present invention to improve upon the storage stability i.e. to enhance the shelf-life of the dosage units.

[0007] The customary amount of Tibolone in the known dosage unit is 2.5 mg in tablets or capsules of 100 mg, i.e. 2.5%. For the sake of providing therapies better tailored to the individual woman's needs, it is desired to provide dosage units having a lower amount.

[0008] However, adaptation of a known formulation by simply including a lower amount of Tibolone further decreases the stability of the dosage unit substantially. E.g., if a 2.5 mg Tibolone dosage unit has a shelf-life of, e.g., 2-3 years at room temperature, the same unit upon lowering the amount of Tibolone to e.g. 0.3 mg can only be kept at 4°C for a period of 6-12 months. Such a lower stability is unacceptable in daily practice. It is a further object of the invention to provide dosage forms having a lower content of Tibolone (which are more prone to stability problems than regular dosage forms) and that can be suitably kept for a prolonged period of time.

[0009] One of the possibilities to keep the amount of Org OM-38 below a desired level also after a prolonged storage time is to limit the amount initially present in the bulk preparation. Thus, there is a need to synthesize high purity Tibolone batches with a low contamination content of Org OM-38. It is an object of the present invention to provide for such high purity batches of Tibolone.

[0010] During the last step of the synthesis of Tibolone a solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of pyridine and ethanol is mixed with a solution of oxalic acid in water and the mixture is stirred for 3 hours at approximately 30 °C. The solution is then poured out in a mixture of pyridine and water and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and subsequently, the crystals are dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (see also van Vliet et al (1986), Recl.Trav.Chim.Pays-Bas 105, 111-115).

[0011] As this compound has a lower stability than the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-pregn-4-en-20-yn-3-one there is always formed a small percentage of the latter compound via acid catalyzed isomerisation.

Furthermore, this isomerisation takes place at higher temperature and upon long term storage of the crystals

[0012] Unexpectedly, it now has been found that the rate of formation of Org OM38 during drying and storage in a specific batch can be decreased if crystals of Tibolone are washed with water and are allowed to age for at least 24 hours in the presence of water. Thus, the Tibolone is left for at least 24 hours under wet conditions. Preferentially the crystals are left under these conditions for a period of at least 3 days. There is no limit to a maximum period but a period of 3-6 days is best suited. The aging temperature preferentially is room temperature.

[0013] Thus according to the procedure of the present invention highly pure Tibolone with a low Org OM38 impurity is obtained by including a delay of several days before drying. The procedure reliably results in batches of Tibolone having a low Org OM38 content. A further advantage is that these batches have an excellent stability. Furthermore, these batches do not form additional amounts of the latter compound upon heating or long term storage.

[0014] The crystal formation procedure of the present invention can perfectly well be combined with the last step of the Tibolone synthesis wherein (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of pyridine and ethanol is mixed with a solution of oxalic acid in water. In general, this reaction proceeds under mild acidic conditions in the presence of an organic solvent and water within a pH range of 5-3, preferentially 3.5-4.5. The acid preferentially is a weak organic acid having a pKa value in the range 1-5 such as citric acid, malonic acid, oxalic acid, dichloroacetic acid and acetic acid, optionally buffered with a base such as pyridine. As organic solvent e.g. ethanol, methanol, acetone, 2-propanol or tetrahydrofuran can be used. The solution is then poured out in water, which is made slightly alkaline by addition e.g. of a low amount of pyridine. After filtering the suspension the crystals are washed with a mixture of water made slightly alkaline by e.g. pyridine. Before drying the crystals are left wet for at least 24 hours.

[0015] Inclusion of the crystal aging step according to the invention results in bulk Tibolone batches with a low Org OM38 content. Routinely, batches are obtained with an Org OM38 content of less than 0.5%. Often even batches with less than 0.25% or even 0.1% of Org OM38 are obtained. Thus high purity compositions with Tibolone having less than 0.5% of Org OM38, preferably 0.25%, more preferably 0.10% of Org OM38 form part of the present invention. The amount of Org OM38 is calculated as the percentage (w/w) of the total amount of the bulk substance including some minor impurities. The amount of Tibolone usually is more than 98%.

[0016] The batches of these high purity Tibolone compositions with their low initial Org OM38 content are perfectly well suited to be used as a source for the preparations of pharmaceutical formulations. This guarantees a formulation with a low initial Org OM38 content and improves therefore its storage properties. Pharmaceutical preparations prepared with high purity Tibolone usually result in preparations with less than 1% of Org OM38, often even less than 0.7% of Org OM38 and these preparations are less prone to increase in Org OM38 content during storage.

[0017] As indicated before the amount of Org OM38 in a dosage form also depends upon the concentration of the active substance, the amount of impurity being higher as the amount of Tibolone in the dosage unit decreases. Therefore, using high purity Tibolone as the active substance, dosage units can now be prepared with a lower amount of Tibolone and still having an acceptable shelf life. Thus, the invention also relates to pharmaceutical dosage units, which can be prepared by admixture of a pharmaceutically suitable solid carrier and the high purity composition of the present invention.

[0018] A typical known formulation for Tibolone is a 100 mg dosage unit having 2.5 mg of Tibolone contained therein, a relatively small amount (e.g. approximately 1 % by weight) of pharmaceutically acceptable auxiliaries, and a carrier making up the body of the tablet. The carrier typically is composed of 10 % by weight of starch, e.g. potato starch, and 90 % by weight of lactose.

[0019] Due to the excellent stability properties of dosage units with a lower amount of active substance than the present commercially available tablets of 2.5 mg active substance, the present invention now makes it also possible to provide for stable dosage units comprising Tibolone in an amount of less than 2.50 mg, preferably 1.25 mg or less, more preferably 0.625 mg or less. At a shelf life of 1.5 years, preferably 2 years these dosage units still comprise less than 5% of OM38 (relative to the amount of Tibolone).

[0020] It is another aspect of the present invention to provide dosage units comprising Tibolone in amounts of less than 2.50 mg, preferably 1.25 mg or less, more preferably 0.625 mg or less and comprising at a shelf life of 6 months less than 3 %, preferably 2 % of OM38. The shelf life preferably is extended up to 1 year, preferably 1.5 year, more preferably 2 years.

[0021] As used herein shelf life means storage during a specified period under temperature conditions varying from 2-25 °C. Dosage units can be packed e.g. in push-through packs (PTP, blister) and are preferably stored in dark (e.g. enclosed in carton). Alternatively they might also be stored in bottles e.g. high-density polyethylene bottles.

[0022] The pharmaceutical dosage units of the present invention will generally take the form of tablets or capsules, but other solid or dry pharmaceutical preparations are included.

[0023] Methods for making such dosage units are well known. For example in the standard English language text Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), methods of making tablets, capsules and pills and their re-

spective components are described.

[0024] Tablets and capsules are prepared of granulates using dry or wet granulation techniques as disclosed in The Theory and Practice of Industrial Pharmacy (Third edition) L. Lachman, H.A. Lieberman and J. L. Kanig (1986) p 1 -99 and 293 - 345.

[0025] The aim of granulation is to improve the flowability and compressibility of the powder mixture. Wet granulation forms the granules by binding the powders (a mixture of a diluent and disintegrant) together with an adhesive. The wet granulation technique employs a solution, suspension or slurry containing a binder, which is usually added to the powder mixture; however the binder may be incorporated dry to the powder mix and the liquid may be added by itself. The wet granulation process is performed in mixers/kneaders or fluid bed systems.

[0026] Usually an amount of water is incorporated in the basic granulate ranging from 5.5 - 7 %. Preferably the amount of water incorporated is at least 6%.

[0027] After granulation the mass is dried to the desired water content using fluid bed dryers, tray dryers, vacuum dryers or other suitable dryers.

[0028] To attain a good distribution of the active (Tibolone) over the total mass, the active is premixed with a part of the granulate, sieved using an oscillating sieve, a high speed sieve or other suitable sieving equipment. Next this mixture is mixed with the remaining part of the granulate and a lubricant. This mixture is compressed to tablets, or filled into capsules.

[0029] The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.

Examples

Example 1

[0030] A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (750 gr) in water (90 litres) and the mixture was stirred for 2 hours at approximately 30 °C. The solution was poured out in a mixture of pyridine (1350 ml) and water (300 litres) and the resulting suspension was filtered. The crystals were washed with a mixture of water and pyridine and dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing 0.6% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 month) indicated a 0.4% increase of the latter compound.

Example 2

[0031] A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (375 gr) in water (90 litres) and the mixture was stirred for 3 hours at approximately 30 °C. The solution was poured out in a mixture of pyridine (1350 ml) and water (300 litres) and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and allowed to age for 3-6 days at room temperature. Subsequently, the crystals were dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing \leq 0.1% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a < 0.1% increase of the latter compound.

Example 3

[0032] The preparation as described in example 2 was repeated. (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one was obtained which contained 0.2 % of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a 0.1% increase of the latter compound.

Example 4

[0033] A basic granulate was prepared by granulation of a mixture of lactose (diluent), potato starch (disintegrant) and potato starch mucilage (binder) in a fluid bed granulator. The water content of the granulate varied within 5.5% - 6.5%. After granulation, the basic granulate was passed through a conical high speed sieve. Part of the granulate (10 % w/w) was mixed with Tibolone and ascorbyl palmitate using a tumble blender and then passed through a conical high speed sieve.

[0034] The Tibolone premix and the remainder of the basic granulate were mixed in a ribbon blender. Magnesium

EP 1 121 375 B1

stearate was added and mixed. The final granulate was compressed into round tablets.

[0035] The stability of the active compound (Tibolone) in tablets was determined.

Table 1:

Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet, in tablets containing a various amount of Tibolone, after storage at 25°C and 60% relative humidity.				
Storage time (months)	Concentration of Tibolone per tablet			
	0.46	0.96	1.92	2.5
	Amount of Org OM38 formed during storage (in percentage of the declared amount of tibolone)			
0	1.2	0.8	0.5	0.4
6	6.5	3.5	1.8	1.6
12	9.5	5.1	2.7	2.2
18	12.2	6.1	3.3	2.7

Example 5

[0036] Tablets of 1.25 mg of Tibolone have been prepared as described in example 4. The tablets were stored at 25°C and 60% relative humidity and the decomposition product (Org OM38) was measured.

Table 2: Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet. Stability of three development tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity).			
Storage time (months)	Batch no		
	049514001	049515001	049516001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)		
0	0.7	1.0	1.3
6	2.3	2.6	2.9
12	3.5	3.7	3.8
18	4.3	4.2	4.3
24	5.1	4.9	4.9

[0037] It can be concluded that the shelf life of tablets containing 1.25 mg of Tibolone per tablet of 65 mg is borderline .

Example 6

[0038] Tibolone as prepared as in example 2 was used as the active compound to prepare tablets as described in example 4. The amount of Org OM38 formed in several batches during storage was determined.

Table 3:

The stability of six tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity). The amount of water incorporated in the basic granulate was varied from 6.0% to 6.5%.						
Storage time (months)	Batch no					
	TD96.1128	TD96.1132	TD96.1133	162454001	162455001	162456001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)					
0	0.7	0.5	0.5	0.9	0.8	0.9

Table 3: (continued)

The stability of six tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity). The amount of water incorporated in the basic granulate was varied from 6.0% to 6.5%.						
Storage time (months)	Batch no					
	TD96.1128	TD96.1132	TD96.1133	162454001	162455001	162456001
Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)						
6	1.3	1.1	1.1	1.8	1.7	1.8
12	1.8	1.5	1.6			
18	2.0	1.5	1.7			
Water content of the basic granulate	6.5	6.5	6.5	6.3	6.1	6.1

Claims

1. A high purity compound (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, **characterized in that** said compound comprises (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5%.
2. The compound according to claim 1 **characterized in that** the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.
3. The compound according to claim 1 **characterized in that** the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.
4. A process for preparing the high purity compound of claims 1-3 **characterized in that** crystals of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one are allowed to age in the presence of water for at least 24 hours.
5. The process according to claim 4 wherein the aging lasts 3-6 days.
6. The process according to claims 4 or 5 **characterized in that** the crystals are formed in the last step of the Tibolone synthesis comprising the steps of
 - a. reacting (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in an organic solvent with a weak acidic aqueous solution
 - b. pouring out the solution in water which is made slightly alkaline
 - c. washing the crystals with water which is made slightly alkaline.
7. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the compound according to any one of the claims 1-3.
8. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the compound obtainable by the process of claims 4-6.
9. A dosage unit comprising a pharmaceutically suitable solid carrier and (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg and comprising less than 5% of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one at a shelf life of at least 1.5 years.
10. The dosage unit according to claim 9 **characterized in that** (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 1.25 mg or less.

11. The dosage unit according to claim 9 **characterized in that** (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 0.625 mg or less.
12. The dosage unit according to claims 9-11 wherein the shelf life is 1.5 years, more preferably 2 years.
13. The dosage unit according to claim 9-11 wherein at a shelf life period of 6 months the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3 % or less, more preferably 2% or less.
14. The dosage unit according to claim 9-11 wherein at a shelf life period of 1 year, preferably 1 ½ year, more preferably 2 years, the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3 % or less, more preferably 2% or less.

Patentansprüche

1. Eine hochreine Verbindung (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on, **dadurch gekennzeichnet, dass** die besagte Verbindung (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on in einer Menge von weniger als 0.5 % umfasst.
2. Die Verbindung gemäss Anspruch 1, **dadurch gekennzeichnet, dass** die Menge an (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on 0.25 % oder weniger ist.
3. Die Verbindung gemäss Anspruch 1, **dadurch gekennzeichnet, dass** die Menge an (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on 0.1 % oder weniger ist.
4. Ein Verfahren zur Herstellung der hochreinen Verbindung gemäss Ansprüchen 1-3 **dadurch gekennzeichnet, dass** man Kristalle von (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on in Gegenwart von Wasser für mindestens 24 Stunden altern lässt.
5. Das Verfahren gemäss Anspruch 4 worin das Altern mindestens 3-6 Tage dauert.
6. Das Verfahren gemäss Ansprüchen 4 oder 5, **dadurch gekennzeichnet, dass** die Kristalle im letzten Schritt der Tibolon-Synthese umfassend die Schritte von
 - a. Reagieren von (7 α ,17 α)-3,3-Dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-on in einem organischen Lösungsmittel mit einer schwach sauren, wässrigen Lösung
 - b. Giessen der Lösung in leicht alkalisch gemachtes Wasser
 - c. Waschen der Kristalle mit leicht alkalisch gemachtem Wasser
- gebildet werden.
7. Eine pharmazeutische Dosiseinheit, die durch Mischen eines pharmazeutisch verträglichen, festen Trägers mit der Verbindung gemäss einem der Ansprüche 1-3 erhältlich ist.
8. Eine pharmazeutische Dosiseinheit, die durch Mischen eines pharmazeutisch verträglichen, festen Trägers mit der Verbindung, die mittels des Verfahrens gemäss Ansprüchen 4-6 erhalten wird, erhältlich ist.
9. Eine Dosiseinheit umfassend einen pharmazeutisch verträglichen, festen Träger und (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on in einer Menge von weniger als 2.50 mg und umfassend weniger als 5 % an (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on mit einer Haltbarkeit von mindestens 1.5 Jahren.
10. Die Dosiseinheit gemäss Anspruch 9 **dadurch gekennzeichnet, dass** (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on in einer Menge von 1.25 mg oder weniger vorhanden ist.
11. Die Dosiseinheit gemäss Anspruch 9 **dadurch gekennzeichnet, dass** (7 α ,17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-on in einer Menge von 0.625 mg oder weniger vorhanden ist.

12. Die Dosiseinheit gemäss Ansprüchen 9-11, worin die Haltbarkeit 1.5 Jahre, mehr bevorzugt 2 Jahre beträgt.
13. Die Dosiseinheit gemäss Ansprüchen 9-11, worin bei einer Haltbarkeitsdauer von 6 Monaten die Menge an (7 α , 17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on 3 % oder weniger, mehr bevorzugt 2 % oder weniger beträgt.
14. Die Dosiseinheit gemäss Ansprüchen 9-11, worin bei einer Haltbarkeitsdauer von 1 Jahr, vorzugsweise 1 ½ Jahren, mehr bevorzugt 2 Jahren die Menge an (7 α , 17 α)-17-Hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-on 3 % oder weniger, mehr bevorzugt 2 % oder weniger beträgt.

Revendications

1. Composé de haute pureté, la (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-5(10)-èn-20-yn-3-one, **caractérisé en ce que** ledit composé comprend la (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one en une quantité inférieure à 0,5%.
2. Composé suivant la revendication 1, **caractérisé en ce que** la quantité de (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one est de 0,25% ou moins.
3. Composé suivant la revendication 1, **caractérisé en ce que** la quantité de (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one est de 0,1% ou moins.
4. Procédé pour la préparation du composé de haute pureté suivant les revendications 1 à 3, **caractérisé en ce que** des cristaux de (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-5(10)-èn-20-yn-3-one sont laissés vieillir en présence d'eau pendant au moins 24 heures.
5. Procédé suivant la revendication 4, dans lequel le vieillissement dure 3 à 6 jours.
6. Procédé suivant les revendications 4 ou 5, **caractérisé en ce que** les cristaux sont formés dans la dernière étape de la synthèse de la Tibolone qui comprend les étapes de :
 - a. réaction de la (7 α , 17 α)-3,3-diméthoxy-17-hydroxy-7-méthyl-19-norprégn-5(10)-èn-20-yn-3-one dans un solvant organique avec une solution aqueuse faiblement acide,
 - b. versement de la solution dans de l'eau qui est rendue légèrement alcaline,
 - c. lavage des cristaux avec de l'eau qui est rendue légèrement alcaline.
7. Dose unitaire pharmaceutique pouvant être obtenue par mélange d'un support acceptable du point de vue pharmaceutique et du composé suivant l'une quelconque des revendications 1 à 3.
8. Dose unitaire pharmaceutique pouvant être obtenue par mélange d'un support acceptable du point de vue pharmaceutique et du composé pouvant être obtenu par le procédé suivant les revendications 4 à 6.
9. Dose unitaire comprenant un support solide acceptable du point de vue pharmaceutique et de la (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-5(10)-èn-20-yn-3-one en une quantité inférieure à 2,50 mg et comprenant moins de 5% de (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one après une durée de vie au stockage d'au moins 1,5 année.
10. Dose unitaire suivant la revendication 9, **caractérisée en ce que** la (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-5(10)-èn-20-yn-3-one est présente en une quantité de 1,25 mg ou moins.
11. Dose unitaire suivant la revendication 9, **caractérisée en ce que** la (7 α , 17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-5(10)-èn-20-yn-3-one est présente en une quantité de 0,625 mg ou moins.
12. Dose unitaire suivant les revendications 9 à 11, dans laquelle la durée de vie est de 1,5 année, de préférence de 2 années.
13. Dose unitaire suivant les revendications 9 à 11, dans laquelle après une durée de vie au stockage de 6 mois, la

EP 1 121 375 B1

quantité de (7 α ,17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one est de 3% ou moins, plus avantageusement de 2% ou moins.

- 5 14. Dose unitaire suivant les revendications 9 à 11, dans laquelle après une durée de vie au stockage de 1 année, de préférence 1,5 année, plus avantageusement 2 années, la quantité de (7 α ,17 α)-17-hydroxy-7-méthyl-19-nor-17-prégn-4-èn-20-yn-3-one est de 3% ou moins, plus avantageusement de 2% ou moins.

10

15

20

25

30

35

40

45

50

55